Evidence map›Paper›PMID 27622386›Full record

ArticleCellular immunology2016

Early treatment with reverse transcriptase inhibitors significantly suppresses peak plasma IFNα in vivo during acute simian immunodeficiency virus infection.

Jeffy George, Lynnsey Renn, Daniela Verthelyi, Mario Roederer, Ronald L Rabin, Joseph J Mattapallil

Open access · greenAbstract read
In one paragraph

Article in Cellular immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Jeffy GeorgeUniformed Services University of the Health Sciences, Bethesda, MD, United States.
Lynnsey RennCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States.
Daniela VerthelyiCenter for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States.
Mario RoedererVaccine Research Center, National Institutes of Health, Bethesda, MD, United States.
Ronald L RabinCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States.
Joseph J MattapallilUniformed Services University of the Health Sciences, Bethesda, MD, United States. Electronic address: joseph.mattapallil@usuhs.edu.
Center for Biologics Evaluation and Research · USUniformed Services University of the Health Sciences · USCenter for Drug Evaluation and Research · USNational Institutes of Health · US

Funding

Mucosal immunity and rectal challengeR01DE019397 · NIDCR · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI MATTAPALLIL, JOSEPH JOHN · 2009 to 2011
$2.4M
NIDCR NIH HHS R01 DE019397
6 · The paper itself

Abstract

Innate interferons (IFN) are comprised of multiple Type I and III subtypes. The in vivo kinetics of subtype responses during human immunodeficiency virus (HIV) infection is not well defined. Using the acute simian immunodeficiency virus (SIV) infection model, we show that plasma IFNα levels peak at day 10 post-infection (pi) after which they rapidly declined. The mRNA expression of Type I and III IFN subtypes were significantly elevated in the lymph nodes (LN) at day 10 pi. Though the expression levels of all subtypes declined by day 14-31 pi, numerous subtypes remained elevated suggesting that ongoing viral replication in LN continues to drive induction of these subtypes. Interestingly, treatment with reverse transcriptase (RT) inhibitors at day 7 pi significantly suppressed plasma IFNα responses by day 10 pi that significantly correlated with cell-associated SIV DNA loads suggesting that RT byproducts such as viral DNA likely plays a role in driving IFN responses during acute SIV infection. Quantification of Type I and III subtype transcripts in sorted subsets of LN CD4+ and CD8+ T cells, CD14+/CD14- monocytes/macrophages, and total CD11c/CD123+ dendritic cells (DC) at day 10 pi showed that DC expressed ∼3-4 log more subtype transcripts as compared to the other subsets. Taken together, our results provide new insights into the kinetics of innate interferon responses during early stages of infection, and provide evidence that DC's are a major in vivo source of innate IFN during acute SIV infection.

Indexed as

Acquired Immunodeficiency SyndromeAcute DiseaseAnimalsCells, CulturedDendritic CellsDisease Models, AnimalDNA, ViralGene Expression RegulationHumansImmunity, InnateImmunosuppression TherapyInterferon-alphaLymph NodesMacaca mulattaReverse Transcriptase InhibitorsSimian Acquired Immunodeficiency SyndromeDNA, ViralInterferon-alphaReverse Transcriptase InhibitorsDendritic cellsHIVIFNαIFNβMucosaSIVSubtypes

Identifiers

PMID27622386
PMCPMC11348878
OpenAlexW2520091797

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.